



image: Shutterstock

Second Announcement

3rd RSC / SCI Symposium on New Therapeutics for Global Health

Monday-Wednesday, 9th - 11th September 2024
Cranfield Management Development Centre,
Cranfield University, Milton Keynes, UK

Call for Abstracts

Abstract submission for poster presentations is now open,
[click here](#) to submit. The abstract submission deadline is
Friday 26th April 2024.

Organised by

Royal Society of Chemistry's Biological and Medicinal Chemistry Sector (RSC BMCS)
Society of Chemical Industry's Fine Chemicals Group (SCI FCG)

Synopsis

Tuberculosis, malaria and diseases caused by a diverse range of pathogens, including flaviviruses (eg dengue, West Nile), kinetoplastids (causative agents of Chagas disease, leishmaniasis, etc) and gut pathogens (worms, bacteria, parasites), remain a cause of high mortality across the globe. Fortunately, an ever-improving understanding of the complex life-cycles of these disease-causing pathogens is presenting increasing opportunities for those seeking to tackle these global health problems.

This meeting will focus on the different approaches being used to develop new therapeutics for diseases that disproportionately affect low- and medium-income countries.

Keynote talks from international experts from industry and academia, alongside perspectives detailing case histories in drug discovery, will highlight the latest developments in the field whilst also showcasing the opportunity for creativity and innovation.

Confirmed speakers

Title TBC

Pedro Alonso, Faculty of Medicine & Hospital Clinic
University of Barcelona

Development of anti-malarial drug discovery in Ghana

Richard K Amewu, University of Ghana

Antimalarial Research & Drug Discovery - tackling the next frontiers

Jeremy Burrows, Medicines for Malaria Venture

New treatments for cryptosporidiosis with optimal properties for targeting gastrointestinal infection

Nicola Caldwell, University of Dundee

Discovering new TB agents for the future with novel modes of action

Laura Cleghorn, University of Dundee

Next Generation Oxazolidinone Antibiotics for the Treatment of Tuberculosis

Brendan Cowley, Merck (MSD)

Design of Potent and Orally Available Antimalarial PMX Inhibitors via Molecular Property Optimization
Teresa De Haro, UCB Biopharma

The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species

Mark Gardner, Salvensis

New Antivirals: AI and Structure Based Open Science and direct-to-generic approaches

Ed Griffin, MedChemica Ltd

Long acting medicines for treatment and prevention of high burden pathogens in low- and middle-income countries

Andrew Owen, University of Liverpool

Identifying new therapeutic options to overcome malaria resistance

Laura M Sanz-Alonso, GSK

Progress and challenges in treating global health diseases

Peter Warner, Bill & Melinda Gates Foundation

Registration, Students & Bursaries

Registration is now open, please [click here](#) to register. For further information on rates and discounts for students, please visit the event website [here](#).

Exhibition

Exhibition and sponsorship is encouraged at this established event with packages starting at £1,500 and £500 respectively, further information on what these packages include can be found on our [website](#).

Venue & Travel

[Click here](#) for information on how to find the venue.

Organising Committee

Giancarlo Biagini, Liverpool School of Tropical Medicine

Martin Lowe, (SCI) (Chair), Exscientia UK

Jayshree Mistry, (SCI) Independent Consultant

Andrew Stachulski, (BMCS) University of Liverpool

Mary Wheldon, (BMCS) (Treasurer), Drug Discovery Unit, University of Dundee



Secretariat contact:

Hg3 Conferences
events@hg3.co.uk
+44 (0) 1423 529333

To find out more, visit the BMCS website by using the URL or by scanning the QR code here:

<https://www.rscbmcs.org/events/ntgh24/>



SCAN ME